Trial Profile

A Phase 1b Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone (Primary) ; Darolutamide (Primary) ; Xaluritamig (Primary)
Indications Adenocarcinoma; Neuroendocrine carcinoma; Prostate cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Amgen

13 Feb 2026 Planned End Date changed from 7 Apr 2030 to 30 Mar 2030.
13 Feb 2026 Planned primary completion date changed from 30 Apr 2028 to 27 Mar 2028.
22 Jan 2026 Protocol has been amended(Time frame of primary endpoint).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com